Funding for this research was provided by:
Ulla-Carin Lindquists stiftelse för ALS-forskning
Vetenskapsrådet (Swedish Research Grant DNR 2019-01088)
Örebro University
Article History
Received: 1 December 2023
Revised: 17 January 2024
Accepted: 20 January 2024
First Online: 22 February 2024
Declarations
:
: Caroline Ingre has consulted for Cytokinetics, Pfizer, BioArctic, Novartis and Tikomed and was a DMC member for Appelis Pharmaceutical. She is also a board member of Tobii Dynavox.
: Ethical approval for the study was obtained from the regional ethical review board in Stockholm (reg. no. 2017/1895-31 and 2022-04337-02. The data used in the study from the SNPR did not include personal identification numbers, thus precluding direct identification of the individual.